Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and Prasugrel

AstraZeneca

Status: Completed

Conditions: Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout

Treatments: Drug: Risk of selected safety events

Study type: Observational

Funder types: Industry

Identifiers

NCT01276275

D5130N00010

Details and patient eligibility

About

The purpose of the study is to describe patient characteristics and drug usage among patients that are prescribed ticagrelor for the first time and to compare them with patients who are prescribed clopidogrel and prasugrel for the first time.

A further purpose is to ascertain and estimate the crude incidence rate of bleeding, arrhythmias, heart failure, acute renal failure, acute liver failure, dyspnoea and gout among new users in the three cohorts of ticagrelor, clopidogrel and prasugrel.

Enrollment: 7,200 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• First time users of ticagrelor, clopidogrel and prasugrel, respectively

Exclusion criteria

• Individuals with more than one of above three antiplatelet drugs dispensed the same day

Trial design

7,200 participants in 3 patient groups

Exposure Group 1

Description:

First time users of ticagrelor

Treatment:

Drug: Risk of selected safety events

Exposure Group 2

Description:

First time users of clopidogrel

Treatment:

Drug: Risk of selected safety events

Exposure Group 3

Description:

First time users of prasugrel

Treatment:

Drug: Risk of selected safety events